S
econd-generation everolimus-eluting stents with durable polymer (DP-EES) reduce cardiac mortality, repeat revascularization procedures and very late stent thrombosis compared with bare metal stents and early generation drug-eluting stents. [1] [2] [3] [4] Notwithstanding this benefit, recent pathology studies suggested a similar frequency of neoatherosclerosis formation in DP-EES as compared with early generation drug-eluting stent (DES), notably one of the leading mechanism leading to very late stent thrombosis and restenosis. 5, 6 Third generation DES has been introduced using biodegradable polymers (BPs) for controlled drug release and refined stent design, including ultrathin stent struts aiming at improving early and late arterial healing with the objective to further reduce stent-related adverse events. The ultrathin strut BP sirolimus-eluting stent (BP-SES, Orsiro) which uses 60 µm strut thickness with circumferential silicon carbide coating, releasing sirolimus during a period of 3 months from a biodegradable poly-L lactic acid layer, was found noninferior to the current standard of DP-EES in recent randomized controlled trials (RCT). [7] [8] [9] [10] [11] BP-SES was also found noninferior to DP-EES in terms of 9-month in-stent late loss (0.10±0.32 versus 0.11±0.29 mm; P for noninferiority <0.001). 9 In the prespecified subgroup of patients presenting with ST-segment-elevation myocardial infarction (STEMI), BP-SES showed superior outcomes compared with DP-EES. 8, 12 Meta-analysis of 8 RCTs revealed a tendency toward a lower risk of MI and stent thrombosis after BP-SES implantation as compared with DP-EES. 13 Notably, BP-SES was associated with lower risk of periprocedural MI as compared with DP-EES. 11 Because RCTs reflect a very controlled setting and typically exclude high-risk patients, the outcomes of ultrathin strut BP-SES in a consecutive patient cohort reflecting routine clinical practice deserves further study. The increased patient and lesion complexity encountered in routine clinical practice may unveil devicerelated differences that did not emerge in patient cohorts eligible for RCT participation.
14 Therefore, we sought to compare clinical outcomes after BP-SES and DP-EES in a prospective all-comer percutaneous coronary intervention (PCI). Registry using propensity score (PS)-matched noninferiority analysis.
METHODS

Study Population
Patients who underwent PCI at Bern University Hospital, Switzerland, were prospectively and consecutively enrolled in the CARDIOBASE Bern PCI Registry. There were no formal patient and lesion exclusion criteria, and all patients who provided informed consent were consecutively enrolled in the registry. In the present analysis, we included exclusively patients treated with ultrathin strut (ϕ 2.25-3.0 mm: 60 µm and ϕ 3.5-4.0 mm: 80 µm) BP-SES (Orsiro, Biotronik AG, Bülach, Switzerland) or thin strut (81 µm) DP-EES (Xience Prime/Xpedition, Abbott Vascular, Abbott Park, IL) and excluded patients who received a different stent type. At Bern University Hospital cathlab, stent types used for PCI are alternated on a daily basis (7 days a week) among the available device types (ie, size and length) independent of scheduled operators, patients, and lesions with the intention to reduce selection bias.
The study complied with the Declaration of Helsinki and was approved by the institutional ethics committee at Bern University Hospital, Switzerland. The registry was registered. The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Procedures
PCI was performed in accordance with current practice guidelines. 15 Unfractionated heparin at a dose of at least 5000 IU or 70 to 100 IU/kg was administered during the procedure. The measurement of activating clotting time was left to the discretion of the operator. All patients received a loading dose of aspirin prior PCI (ie, 250 mg). Loading dose of P2Y 12 inhibitor was administered before, at the time, or immediately after the procedure, unless maintenance dose of P2Y 12 inhibitor had been prescribed previously. Prasugrel was routinely used in patients presenting with STEMI as of September 2009, and ticagrelor was routinely used in those presenting non-ST-segment elevation acute coronary syndrome as of November 2011.
WHAT IS KNOWN
• Ultrathin strut biodegradable polymer sirolimuseluting stent (BP-SES) has been reported to be noninferior compared with second-generation everolimus-eluting stents with durable polymer (DP-EESs) in randomized clinical trials.
• BP-SES showed superior outcomes compared with DP-EES in prespecified subgroup of patients presenting with ST-segment-elevation myocardial infarction in the BIOSCIENCE randomized clinical trials.
• BP-SES was associated with lower risk of periprocedural myocardial infarction as compared with DP-EES in the BIOFLOW V randomized clinical trials.
WHAT THE STUDY ADDS
• In the consecutively enrolled percutaneous coronary intervention population reflecting routine clinical practice, we confirmed noninferiority of BP-SES as compared with DP-EES in terms of primary deviceoriented composite end point at 1 year.
• BP-SES was marginally associated with lower risk of device-oriented composite end point as compared with DP-EES in patients presenting with ST-segment-elevation myocardial infarction, while no significant difference was observed between BP-EES versus DP-EES with regards to periprocedural myocardial infarction.
Patient Follow-Up
All patients included in the registry were systematically and prospectively followed throughout at least 1 year to assess major adverse cardiac events, including death, cardiac death, MI, target vessel revascularization, target lesion revascularization (TLR), and definite or probable stent thrombosis. Survival data were obtained from hospital records and municipal civil registries. A health questionnaire was sent to all living patients with questions on rehospitalization and adverse events, followed by telephone contact in case of missing response. General practitioners, referring cardiologists, and patients were contacted as necessary for additional information. For patients who underwent treatment for adverse events at other medical institutions, external medical records, discharge letters, and coronary angiography documentation were systematically collected and reviewed. An independent clinical event committee consisting of 2 cardiologists (and in case of disagreement of a third referee) adjudicated all events using original source documents. In case of any coronary revascularization, we evaluated the angiography to distinguish TLR from non-TLR. All data were prospectively stored in a central database (Cardiobase, Clinical Trials Unit, and Department of Cardiology, Bern University Hospital, Switzerland, and 2mT, Ulm, Germany).
Clinical End Points and Definitions
The primary end point was the device-oriented composite end point (DOCE), including cardiac death, target vessel MI, and TLR. Cardiac death was defined as any death because of an immediate cardiac cause, procedure-related mortality, and death of unknown cause. MI was defined according to the modified historical definition. 16 The diagnosis of Q-wave MI required ischemic signs or symptoms and new pathological Q waves in ≥2 contiguous ECG leads. Target vessel MI was defined as MI not clearly attributable to a nontarget vessel. Periprocedural MI was adjudicated according to the modified historical definition (Methods in the Data Supplement). 16 Stent thrombosis was adjudicated based on Academic Research Consortium criteria. 17 TLR was defined as any revascularization for a stenosis within the stent or the 5 mm borders adjacent to the stent. Target vessel revascularization was defined as repeat revascularization of any segment within the entire major coronary vessel proximal and distal to a target lesion.
Statistical Analysis
This was a PS-matched noninferiority analysis, which was powered for noninferiority on the primary end point in composite end point of DOCE. In the BIOSCIENCE trial, the incidences of a composite of cardiac death, target vessel MI, and clinically indicated TLR were 6.7% in both BP-SES and DP-EES arms. 8 Accounting for the rate of nonclinically indicated TLR and greater risks for patients included in the all-comer registry as compared with those included in the RCT, we assumed a rate of the primary end point of 8% at 12 months in both groups. An absolute risk margin of 3.5% was used for the assessment of noninferiority comparing BP-SES with the DP-EES. 8, 18, 19 Enrollment of 2060 patients was calculated to provide >80% power to detect noninferiority at a 1-sided type I error of 0.05. Noninferiority would be claimed if the upper limit of the 1-sided 95% CI of the absolute risk difference was not >3.5%. The 1-sided P value for noninferiority was calculated from a Z test comparing differences between groups with the margin of noninferiority. The primary end point noninferiority test includes all patients because the margin was defined and tested by protocol on a risk difference scale, which cannot take into account censoring of patients.
We used PS matching to account for differences in baseline characteristics. PS for receiving the BP-SES versus DP-EES were estimated using a probit regression model, including clinical and lesion characteristics listed in Tables 1 and 2 as explanatory variables. An automated matching procedure randomly selected a patient treated with BP-SES, and a randomly selected patient treated with DP-EES from the pool of patients with PS within a caliper of <0.05 on the PS. Because the clinical presentation was likely to be a bias for selection of DES type and was a prespecified study target based on the previous findings of BIOSCIENCE study, in which there was a significant interaction between STEMI presentation and DES type, 8 matched pairs were chosen within each stratum of patients presenting with STEMI, non-STEMI, unstable angina, and stable coronary artery disease to diminish the risk of imbalances in clinical presentation.
To identify independent predictors of primary end point of DOCE within 1 year, we constructed a multivariable Weibull regression survival model, including baseline patient characteristics listed in Table 1 as exploratory variables. A model was chosen based on minimal Akaike Information Criterion using backward stepwise. Variables with Wald-type P value <0.05 were identified as independent predictors for DOCE. We regarded patients with at least 1 of the predictors as high-risk patients.
Categorical variables were compared with Fisher exact test. Continuous variables were expressed as mean value±SD and compared with unpaired t test. Lesion characteristics were compared between the groups using mixed models accounting for lesions nested within patients. Cumulative incidences for the first events were estimated by the KaplanMeier method. All patients were analyzed up to and including the last valid contact date or at 12 months and censored at the time point of last contact if they were lost to follow-up. Hazard ratios (HRs) were calculated from Weibull regression survival models comparing BP-SES and DP-EES.
Statistical analyses were performed with the use of Stata version 14.2. All the statistical analyses were 2-tailed, apart from noninferiority testing of the primary end point. P values <0.05 were considered statistically significant.
RESULTS
Baseline Characteristics
Between March 2011 and June 2015, a total of 7640 patients (12562 lesions) were consecutively enrolled in the CARDIOBASE Bern PCI Registry. For the present analysis, we excluded 224 patients who did not undergo stent implantation, 2508 patients receiving other stent types, and 270 patients who had been treated with several different stent types. Finally, we included 4638 patients who underwent PCI exclusively with BP-SES (1896 patients, 3137 lesions) or DP-EES (2742 patients, 4468 lesions; Figure 1 ). There was a significant difference in baseline characteristics between patients included in this study (N=4638) and those not included (other stents used: N=2508; mixed of target and nontarget stents used: N=270; no stenting: N=224), mostly driven by those with heterogeneous stent used (Table I in the Data Supplement). Depicted are counts (%, P values from Fisher tests) and means with SDs (P values from unpaired t tests). eGFR (mL/ min per 1.73 m2), calculated using the Cockcroft-Gault formula. BP-SES indicates biodegradable polymer sirolimuseluting stent; DP-EES, durable polymer everolimus-eluting stent; eGFR, estimated glomerular filtration rate; and PCI, percutaneous coronary intervention.
*Variables included in the multivariable analysis to estimate propensity score for receiving the BP-SES vs DP-EES.
Baseline patient and lesion characteristics before and after PS matching are provided in Tables 1 and 2; Tables  II and III Table 3 ). In a total of 128 patients who did not received DAPT at discharge, either oral anticoagulation or novel oral anticoagulation was administered in 40.5% of patients treated with BP-SES and in 36.7% of patients treated with DP-EES. Of note, DAPT was less often prescribed at 1 year in patients treated in the later half 
Clinical Outcomes
Clinical follow-up information was obtained in 2717 (93.6%) patients at 1 year without differences between groups of patients treated with BP-SES (N=1365; 94.1%) or DP-EES (N=1352; 93.2%; P=0.36; Figure 1 ). Cumulative rates of cardiovascular adverse events are summarized in Table 4 and Figure 2 . BP-SES was noninferior in terms of the primary end point of DOCE as compared with DP-EES (6.9% versus 8.0%; HR, 0.85; 95% CI, 0.65-1.11; P for noninferiority <0.001; P for superiority=0.24). There were no significant differences between BP-SES and DP-EES with regards to the individual components of the primary end point cardiac death (2.3% versus 3.0%; HR, 0.76; 95% CI, 0.49-1.20; P=0.25), target vessel MI (3.3% versus 3.6%; HR, 0.94; 95% CI, 0.63-1.39; P=0.75), and TLR (2.8% versus 2.5%; HR, 1.11; 95% CI, 0.71-1.74; P=0.65). We measured creatine kinase at postprocedure in 96.9% of patients and at both baseline and postprocedure in 89.1% of patients (Table V in the Data Supplement). No significant difference was observed with regards to periprocedural MI (2.1% versus 2.2%; HR, 0.97; 95% CI, 0.59-1.58; P=0.89). The rate of definite stent thrombosis was similarly low in both groups throughout 1 year (0.8% versus 0.8%; HR, 1.00; 95% CI, 0.42-2.22; P=1.00).
Stratified analyses for the primary end point of DOCE are shown in Figure 3 . No significant interaction was observed in the respective subgroups. Although BP-SES was marginally associated with lower risk of DOCE as Depicted are counts (%, P values from Fisher tests or Mixed models accounting for lesions nested within patients); or means with SDs (P values from Mixed models accounting for lesions nested within patients). Missing values were described in Methods in the Data Supplement. BP-SES indicates biodegradable polymer sirolimus-eluting stent; DP-EES, durable polymer everolimus-eluting stent; PCI, percutaneous coronary intervention; TIMI, Thrombolysis In Myocardial Infarction; and TLR, target lesion revascularization.
†Percutaneous transluminal catheter angioplasty (PTCA) alone was performed in a minority of patients receiving first the study stent and second PTCA in another lesion (which did not count for TLR).
‡Restenotic lesions include in-stent restenosis and those previously treated with balloon dilatation only.
compared with DP-EES in patients presenting with STEMI (HR, 0.54; 95% CI, 0.30-0.97; P=0.04), no significant differences between BP-SES and DP-EES were observed in patients presenting with non-STEMI (HR, 1 Figure I in the Data Supplement).
Using multivariable Weibull regression survival model, including baseline patient characteristics listed in Table 1 as exploratory variables, we identified diabetes mellitus, coronary artery disease, multivessel treatment, renal failure, thrombocytopenia, current smoker, Killip III or IV, hemodynamic support, and ≥3 treated lesions as independent predictors for DOCE at 1 year. In patients with at least one of the predictors (BP-SES, N=1171 and DP-EES, N=1175), no significant difference was observed at 1 year in terms of DOCE between BP-SES group (7.8%) and DP-EES group (8.8%; HR, 0.89; 95% CI, 0.67-1.19; P=0.44; Table VI in the Data Supplement).
DISCUSSION
The present PS-matched noninferiority analysis comparing BP-SES and DP-EES in a consecutively enrolled PCI cohort representing routine clinical practice has the following salient findings: 18 BP-EES, and DP zotarolimus-eluting stent. 19 To the best of our knowledge, the present study is the first all-comer large-scale registry of consecutively enrolled patients to confirm noninferiority of ultrathin strut BP-SES to DP-EES for clinical efficacy as indicated by TLR, as well as comparable safety in terms of cardiac death, MI, and definite stent thrombosis throughout 1 year. The incidence of DOCE after DP-EES (8.0%) was closely corresponding with the assumptions of the statistical analysis plan (8%), attesting to the robustness of the present analysis. The incidence of all-cause death at 1 year in our registry was higher (≈4%-5%) compared with previous RCTs (≈3% in BIOSCIENCE, 8 1% in SORT OUT VII, 18 and 2% in BIO-RESORT 19 ), reflecting the unselected inclusion of patients, including high-risk PCI population. Of note, 24.5% of patients had renal failure (glomerular filtration rate <60 mL/min) while frequency of patients with renal failure were generally low in RCTs (eg, 14.0% in BIOSCIENCE 8 ). Cardiogenic shock, usually excluded in any RCT, was present in 2.5% of patients. To test the impact of stent type in high-risk patients who are likely to be included in allcomer registry rather than RCT, we divided patients into 2 groups according to the presence or absence of at least 1 high-risk characteristics. No significant difference was also observed between BP-SES and DP-EES with regards to primary end point of DOCE in patients with high-risk features, such as diabetes mellitus, coronary artery disease, multivessel treatment, renal failure, thrombocytopenia, current smoker, Killip III or IV, hemodynamic support, and ≥3 treated lesions. The reference arm DES (DP-EES) showed favorable results leaving little room for improvement with a notable trend towards superiority in terms of DOCE for BP-SES as compared with DP-SES. Because BP stents are less likely to unfold their benefit within 1 year, refined stent design with ultrathin struts might contribute to improved outcomes during longer-term observations.
Using identical definitions of MI, the incidence of MI (BP-SES: 4.6% and DP-EES: 4.6%) in our cohort was almost equivalent with those in the BIOSCIENCE study (BP-SES: 3.9% and DP-EES: 4.4%), extending the notion of a similar safety profile to higher risk patients. Although the real clinical impact of MI events captured by prospectively followed registry remains a matter of debate, 20, 21 it is noteworthy that approximately half of MI was target vessel non-Q-wave MI, and most were procedure-related MI (BP-SES: 2.1% and DP-EES: 2.2%). In the BIOFLOW V RCT, the primary end point of 12-month target lesion failure was less frequently observed in patients treated with BP-SES as compared with DP-EES (6% versus 10%; P=0.04), mainly driven by smaller risk of periprocedural MI after BP-SES implantation (2% versus 4%; P=0.04). 11 In the previously conducted RCTs, the 12-month rate of MI after DP-EES implantation ranged from 1% to 5%, except for BIOFLOW V RCT (9%; Figure II in the Data Supplement). In the present all-comer registry, no significant difference in terms of periprocedural MI was observed between BP-SES versus DP-EES (2.1% versus 2.2%; P=0.89), by application of the modified historical periprocedural MI definition. At 1 year, TLR (≈3%) and ST (<1%) were rather low in both groups attesting to the recent advances achieved even in routine clinical practice PCI populations. Although 3-year follow-up of RCTs comparing BP biolimus-eluting stents (strut thickness, 120 µm) and DP-EES showed similar rates of TLR and ST, 22, 23 long-term follow-up is required to fully elucidate the clinical impact of BP in combination with refined strut design. In the prespecified STEMI subgroup analysis of BIOSCIENCE study, a composite of cardiac death, target vessel MI, and clinically indicated TLR was less often observed in STEMI patients treated with BP-SES as compared with DP-EES (3.4% versus 8.8%; P=0.02), mainly driven by tendencies towards lower rates of cardiac death (1.5% versus 4.7%; P=0.062) and target vessel MI (0.5% versus 2.6%; P=0.08). In the present analysis, while no significant interaction between clinical presentation and stent type was observed, we also observed a tendency toward benefit of BP-SES as compared with DP-EES in STEMI patients with regard to the primary end point of DOCE (HR, 0.54; 95% CI, 0.30-0.97; P=0.04; P for interaction=0.12). Further randomized trials are needed to confirm the potential benefit of BP-SES in patients with STEMI.
According to the previous American and European guidelines, 15, 24 DAPT was recommended to be administered for 12 months after new-generation DES implantation. In the BIOSCIENCE study, 78.4% of patients received DAPT at 1 year, 8 whereas 85.6% of patients Depicted are first events (% from Kaplan-Meier estimate), Hazard ratios from Weibull survival models comparing BP-SES vs DP-EES (with 95% CI) and P values. DOCE is the primary outcome, defined as the composite of cardiac death, TV-MI, and TLR. POCE is the patient-oriented outcome, defined as the composite of all-cause death, MI, including periprocedural (creatine kinase >2 ULN, if not available creatine kinase-MB >3 ULN), and any revascularization. BP-SES indicates biodegradable polymer sirolimus-eluting stent; CAD, coronary artery disease; DOCE, device-oriented composite end point; DP-EES, durable polymer everolimus-eluting stent; MI, myocardial infarction; and TLR, target lesion revascularization.
*Stable CAD patients only, days because index procedure the peak occurred entered into the model (0-5 d).
received DAPT at 1 year in the BIO-RESORT study. 19 In our registry, ≈75% of patients received DAPT at 1 year, which was consistent with previous RCTs. We could not deny possibility that the observed difference in the rate of DAPT at 1 year between BP-SES and DP-EES (77.7% versus 72.9%; P=0.01) might have an influence on the occurrence of adverse events during the first year after stent implantation.
Limitations
The present analysis has several limitations. First, this was not a randomized comparison between BP-SES and DP-EES and results may be biased. Indeed, we observed differences in baseline clinical and procedural characteristics between the 2 groups in the unmatched population; the potential of bias was nonetheless minimized after PS matching. Second, noninferiority hypothesis was not prespecified before enrollment of the first patient. Furthermore, noninferiority margin of 3.5% was determined arbitrary, even though based on previous publications. Third, although we included a total of 2902 matched patients, the study was unpowered to detect differences in individual safety and efficacy parameters, such as cardiac death, MI, and stent thrombosis. Largerscale studies are needed to clarify these observations. Fourth, as it is not possible by definition to include medication status after the index procedure into the PS generating model, the minor imbalances with regard to DAPT status may have modified clinical outcomes. Fifth, since we conducted the PS matching analysis to correct for selection biases, outliers (ie, very/extremely high-risk/lowrisk patients) might be excluded during the PS matching process. Sixth, there was a significant difference in baseline characteristics between patients included in this study and those not included, suggesting a selection bias. Of note, limiting patients who treated with a single DES type might decrease generalizability. Seventh, the independent clinical event committee was not blinded to the DES used. The cardiologists were unaware of any planned registry analyses at the time of events adjudication. Thus, the risk of assessment bias is minuscule. Eighth, the high number of STEMI and non-STEMI patients included in the analysis might mask the difference in the incidence of periprocedural MI. Finally, clinical follow-up duration was limited to 1 year. As the benefit of BP is expected to be unfolded at a later time point beyond its absorption, longer follow-up studies are required to test whether BP reduce the late adverse events, such as very late stent thrombosis beyond 1 year.
Conclusions
In the consecutively enrolled PCI population reflecting routine clinical practice, BP-SES was noninferior to DP-EES for DOCE throughout 1 year. No differences were observed with respect to individual efficacy and safety outcomes, including MI, TLR, and ST. 
